Polypeptide Group
PolyPeptide Group AG is a Swiss Contract Development and Manufacturing Organization (CDMO) specializing in custom peptide and oligonucleotide manufacturing for the pharmaceutical industry. The company provides peptide API synthesis, process development, analytical testing, and commercial-scale GMP peptide manufacturing for therapeutic applications. Main revenue drivers consist of CDMO research and process development fees, clinical-stage trial batch manufacturing charges, and commercial peptide API sales billed to biopharmaceutical clients. PolyPeptide Group serves global biopharmaceutical corporations, biotechnology developers, and generic drug makers across North America, Europe, and Asia. The company holds a world-dominant market position as one of the premier specialized CDMOs for therapeutic peptide synthesis. Headquartered in Baar, Zug, Switzerland, PolyPeptide Group AG is listed on the SIX Swiss Exchange.
2 of the funds FundTelligence covers report a position in Polypeptide Group.
- Legal name
- Polypeptide Group AG
- Sector
- Health Care
- Country
- Switzerland
- Funds holding it
- 2
Funds holding Polypeptide Group
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)